Healthcare · 13.3

Biotechnology

Quantified news impact based on deduplicated, quality-reviewed events in a single 60-day window.

Average net impact+22weighted per event

Average gross impact28absolute weighted average

Events28same period

Confidence76%model average

Raw intensity58before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed0.5 / day

Concentration5%

Direction disagreement20%

Source independence100%12 sources

IMPACT TREND

60-day effective impact

Positive 24 · Negative 2 · Mixed 2

+230-23

3 Jun0 events

8 Jun0 events

13 Jun0 events

18 Jun0 events

23 Jun0 events

28 Jun0 events

3 Jul0 events

8 Jul0 events

13 Jul0 events

18 Jul0 events

+22

23 Jul15 events

+23

28 Jul13 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term37%288 cumulative effective impact

Medium term51%394 cumulative effective impact

Long term13%98 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 1 of 3 · 28 events

Macro0

No evidence on this page.

Industries4

Industries29 Jul, 21:00positive

China's Innovative Drug Out-Licensing Hits 81 Deals ~$110 Billion in H1 2026; 38 Class 1 Drugs Approved

In the first half of 2026, China's innovative drug out-licensing reached 81 deals valued at about $110 billion, already 80% of the full-year 2025 total. Meanwhile, 38 Class 1 innovative drugs were approved for market, including 11 with new targets and mechanisms, all domestically developed. Chinese companies accounted for eight of the top ten global pharmaceutical deals, and total deal value represented about 70% of global M&A. The period also saw the first AI-discovered drug enter Phase III trials in China.

Effective: +53
Intensity: 80
Confidence: 85%
Horizon: Medium term

Industries30 Jul, 20:00positive

China Insurance Association Completes Drug Selection for Commercial Insurance List; NHSA to Expand Innovative

The China Insurance Association, under the National Financial Regulatory Administration, has completed preliminary drug selection for its commercial insurance drug list, which is pending release. The list differs from the NHSA's commercial insurance innovative drug list and is for pure commercial health insurance. In 2026, the NHSA will expand its innovative drug list for the first time, requiring drugs with strong insurance suitability. Submissions for the NHSA list in 2026 are less than half of 2025. The first NHSA list faced challenges in Huiminbao products, including incomplete discount channels. Alzheimer's drugs lecanemab and donanemab entered national medical insurance in 2026 and are in multiple Huiminbao products. The China Insurance Association is also developing a drug guarantee list to standardize commercial insurance drug lists.

Effective: +51
Intensity: 75
Confidence: 85%
Horizon: Short term

Industries28 Jul, 19:26positive

15 Pharma Firms in 2026 Fortune 500; Eli Lilly Jumps to 224th as Tirzepatide Tops Global Drug Sales

The 2026 Fortune Global 500 lists 15 pharmaceutical companies, unchanged from 2025 but with reshuffled rankings. Eli Lilly posted the largest leap, rising 112 spots to 224th, with revenue surging 44.7% to $65.179 billion and profit soaring 94.9% to $20.64 billion. Its GLP-1 drug tirzepatide generated $36.507 billion in sales, surpassing Novo Nordisk's semaglutide ($36.1 billion) to become the world's best-selling medicine. Novo Nordisk also gained 35 places, and both companies led profit margins among pharma peers.

Effective: +37
Intensity: 70
Confidence: 85%
Horizon: Medium term

Industries27 Jul, 11:15positive

New EEG Device Enables Cross-Regional Synchronous Collection from Thousands, Boosts Brain-Engineering Stocks

Chinese research teams released a novel EEG signal acquisition device that, for the first time globally, enables synchronous collection from over a thousand people across different regions, marking a key step in neural model training and brain-computer interface development. The news drove brain-engineering concept stocks higher, with Aipeng Medical hitting the 20% daily limit, Beiyikang surging over 17%, Chengdu Huawei over 15%, and Sanbo Brain and Beiqingsong each rising over 10%.

Effective: +37
Intensity: 75
Confidence: 80%
Horizon: Short term

Companies5

Companies28 Jul, 19:04positive

Henlius Serplulimab First to Show Positive Post-Surgery Chemo-Free Result in Gastric Cancer at ASCO

At the 2026 ASCO annual meeting, Peking University Cancer Hospital's Professor Shen Lin presented the ASTRUM-006 phase III study, showing that Henlius' serplulimab achieved the first global positive result for a post-surgery chemotherapy-free regimen in perioperative gastric cancer. The trial involved 57 centers and 588 patients, with a design of three cycles of preoperative chemo-immunotherapy followed by up to 17 cycles of immunotherapy alone. The study met its primary endpoint of event-free survival at the interim analysis in October 2025. Nearly half of gastric cancer patients worldwide are in China, and the Western triple chemotherapy regimen is applicable to less than 10% of East Asian populations. Over the past 30 years, the five-year survival rate for gastric cancer has improved from about 20% to 40-50%.

Effective: +52
Intensity: 85
Confidence: 80%
Horizon: Medium term

Companies30 Jul, 21:56positive

Argenx to Acquire Forte Biosciences for $2.2 Billion in Cash, a 40.5% Premium, Gaining Anti-CD122 Asset FB102

Argenx announced on July 27, 2026, an all-cash acquisition of Forte Biosciences for approximately $2.2 billion, or $77 per share, a 40.5% premium over the prior close. The deal, Argenx's first since its Nasdaq listing, targets FB102, an anti-CD122 antibody modulating IL-12/IL-15 signaling. Phase 1b data for FB102 showed statistically significant benefits in celiac disease and vitiligo, with no serious adverse events.

Effective: +48
Intensity: 75
Confidence: 83%
Horizon: Medium term

Companies27 Jul, 14:35positive

Johnson & Johnson's MonumenTAL-6: Tecvayli+Talvey Cuts Myeloma Progression Risk 89%, Death 62%

Johnson & Johnson released phase 3 MonumenTAL-6 data showing that the combination of bispecific antibodies Tecvayli and Talvey reduced the risk of disease progression or death by 89% and the risk of death by 62% in patients with multiple myeloma who had received two to five prior lines of therapy. The trial enrolled patients previously treated with a CD38 antibody, with about 80% being resistant to daratumumab. The first interim analysis met both progression-free survival and overall survival endpoints.

Effective: +47
Intensity: 78
Confidence: 82%
Horizon: Medium term

Companies29 Jul, 18:24positive

Hengrui's Shudi Insulin Injection Approved as China's First Homegrown Long-Acting Insulin Analogue

Hengrui Medicine announced on July 29 that its independently developed Class 1 biologic Shudi Insulin Injection has been approved by the National Medical Products Administration (NMPA) for market launch. The product is China's first domestically developed long-acting insulin analogue.

Effective: +42
Intensity: 70
Confidence: 80%
Horizon: Medium term

Companies27 Jul, 18:04positive

CSPC Pharmaceutical Group Expects Interim Profit of RMB5.9-6.2 Billion, Up 132%-143%

CSPC Pharmaceutical Group issued a profit alert, expecting interim profit attributable to shareholders of approximately RMB5.9 billion to RMB6.2 billion, a year-on-year increase of 132% to 143%. The surge was driven by a sharp rise in licensing fee revenue, including US$840 million in upfront payments recognized in the second quarter. Additionally, the group's finished drug business saw sales revenue rise about 10% year-on-year, supporting overall profitability.

Effective: +36
Intensity: 70
Confidence: 85%
Horizon: Short term